PRQR (ProQR Therapeutics NV) Cyclically Adjusted Revenue per Share: $0.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRQR ProQR Therapeutics NV PRQR
48 GF Score
Price $1.72
GF Value $2.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Cyclically Adjusted Revenue per Share?

ProQR Therapeutics NV PRQR -3.91% 48 Cyclically Adjusted Revenue per Share is $0.13 as of Mar. 2026. GuruFocus rates PRQR with a GF Score™ of 48/100 and a GF Value™ of $2.05 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ProQR Therapeutics NV's adjusted revenue per share for the three months ended in Mar. 2026 was $0.022. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ProQR Therapeutics NV's average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-25), ProQR Therapeutics NV's current stock price is $1.72. ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.13. ProQR Therapeutics NV's Cyclically Adjusted PS Ratio of today is 13.23.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ProQR Therapeutics NV was 57.50. The lowest was 9.33. And the median was 20.97.


ProQR Therapeutics NV  (NAS:PRQR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ProQR Therapeutics NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.72/0.13
=13.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ProQR Therapeutics NV was 57.50. The lowest was 9.33. And the median was 20.97.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Related Terms


ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.06 0.11 0.13

ProQR Therapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.12 0.13 0.13

PRQR vs CRBP, NRXP, CRBU: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted PS Ratio falls into.


PRQR
48GF Score
ProQR Therapeutics NV PRQR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ProQR Therapeutics NV's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.022/136.9100*136.9100
=0.022

Current CPI (Mar. 2026) = 136.9100.

ProQR Therapeutics NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 100.260 0.000
201609 0.000 100.570 0.000
201612 0.000 100.710 0.000
201703 0.000 101.440 0.000
201706 0.000 101.370 0.000
201709 0.000 102.030 0.000
201712 0.000 101.970 0.000
201803 0.000 102.470 0.000
201806 0.000 103.100 0.000
201809 0.000 103.950 0.000
201812 0.000 103.970 0.000
201903 0.000 105.370 0.000
201906 0.000 105.840 0.000
201909 0.000 106.700 0.000
201912 0.000 106.800 0.000
202003 0.000 106.850 0.000
202006 0.000 107.510 0.000
202009 0.000 107.880 0.000
202012 0.000 107.850 0.000
202103 0.000 108.870 0.000
202106 0.004 109.670 0.005
202109 0.015 110.790 0.019
202112 0.003 114.010 0.004
202203 0.017 119.460 0.019
202206 0.014 119.050 0.016
202209 0.011 126.890 0.012
202212 0.011 124.940 0.012
202303 0.009 124.720 0.010
202306 0.016 125.830 0.017
202309 0.018 127.160 0.019
202312 0.044 126.450 0.048
202403 0.059 128.580 0.063
202406 0.083 129.910 0.087
202409 0.052 131.610 0.054
202412 0.045 131.630 0.047
202503 0.046 133.330 0.047
202506 0.042 133.960 0.043
202509 0.032 135.920 0.032
202512 0.052 135.270 0.053
202603 0.022 136.910 0.022

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.13 mean?
ProQR Therapeutics NV (PRQR) has a Cyclically Adjusted Revenue per Share of $0.13 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share too high?
ProQR Therapeutics NV's current Cyclically Adjusted Revenue per Share is $0.13. Overall, ProQR Therapeutics NV has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share compare to CRBP and NRXP?
ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share of $0.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Cyclically Adjusted Revenue per Share is $0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, ProQR Therapeutics NV (PRQR) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.05, compared to a current price of $1.72 — trading 16.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.13. ProQR Therapeutics NV's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ProQR Therapeutics NV (PRQR), the current Cyclically Adjusted Revenue per Share is $0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (PRQR) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of $1.72 is trading 16.1% below its estimated GF Value™ of $2.05. GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.

Key valuation signals for PRQR:

  • Cyclically Adjusted Revenue per Share: $0.13
  • GF Value™: $2.05 vs. price of $1.72 (16.1% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the PRQR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ProQR Therapeutics NV Business Description

Other Exchanges 0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
48GF Score

Get the complete analysis for PRQR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price
$2.05
GF Value